DETERMINATION OF THE MEDIUM VALUE OF SOME CHEMICAL INDICATORS IN SCREENING PRIVATE (FREE β-HCG, PAPP–A, NT)

Văn Thạo Tạ 1,2,, Thị Như Quỳnh Nguyễn1, Thị Mai Hương Nguyễn1, Thị Thùy Trang Dương 1
1 Hanoi medical university
2 CHEMEDIC VIETNAM JOINT STOCK COMPANY

Main Article Content

Abstract

Congenital anomaly are one of the most common abnormalities in fetuses and newborns. There are many causes of congenital anomaly, of which genetic disorders at the chromosomal level have the most severe consequences. To diagnose chromosomal abnormalities, before conducting invasive pregnancy tests, laboratories are assigned double test in pregnancy I or triple test in pregnancy II. For the dual trial, the quantitative results of β-HCG and blood PAPP-A, combined with ultrasound results such as nuchal translucency (NT), rumpback length (CRL) will be converted to the multiple center MoM in the week of the clothes, calculating the risk value of disease for each fetus according to the possible rate of determination.  This value is subject to change in the pre-feature to the percestation 7. Several recent studies have shown the difference between average value in the experimental population and the software, from available parts, thus helping complete the accuracy and reliability of the filtered value.  We therefore do this study to determine the central MoM values ​​of some biochemical indicators in prenatal screening (β-HCG, PAPP-A and NT). We conducted a survey on 1265 pregnant women who were double test with gestational weeks from 11 weeks to 13 weeks and 6 days respectively. According to the results, there is a difference in β-HCG, PAPP-A, NT in our study compared to those used in other brands, specific values ​​are in the content of the article. The median MOM value after being established for effective prenatal screening in Vietnamese pregnant women.

Article Details

References

1. Đỗ Thị Thanh Thủy, Nguyễn Thị Hồng Phương. Xác Lập Các Giá Trị Trung vị Cho Bộ Ba Xét Nghiệm Sàng Lọc Trước Sinh Bằng Kỹ Thuật ELISA (Gamma Kit) Trên Máy Bán Tự Động. Tạp chí Y học Thành phố Hồ Chí Minh 280–288.
2. Nguyễn Việt Hùng, Trịnh Văn Bảo. Nghiên cứu tình hình dị tật bẩm sinh của sơ sinh đẻ tại bệnh viện Bạch Mai từ 1/1/1999 đến 30/9/2003 và một số yếu tố liên quan. Tạp chí Y học thực hành. 2005;3(505):12-16.
3. Benn PA, Clive JM, Collins R. Medians for second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol; differences between races or ethnic groups. Clin Chem. 1997;43(2):333-337.
4. Breathnach FM, Malone FD, Lambert-Messerlian G, et al. First- and second-trimester screening: detection of aneuploidies other than Down syndrome. Obstet Gynecol. 2007;110(3):651-657.
5. Bolar K, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in turner syndrome. J Clin Endocrinol Metab. 2008;93(2):344-351.
6. Christian A.D. et al. Global Report on Birth Defects. March of Dimes 2006; 2-20.
7. Muzaffer Katar. Determination of Median Values of First Trimester Screening Tests: A Tokat Scale Retrospective Study. Van Sag Bil Derg 2019;12(2):15-21.
8. Hsu JJ, Hsieh TT, Hsieh FJ. Down syndrome screening in an Asian population using alpha-fetoprotein and free beta-hCG: a report of the Taiwan Down Syndrome Screening Group. Obstet Gynecol. 1996;87(6):943-947.